PTC Therapeutics (NASDAQ:PTCT) Director Sells $795,000.00 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Emma Reeve sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $79.50, for a total value of $795,000.00. Following the transaction, the director owned 6,666 shares of the company’s stock, valued at approximately $529,947. This trade represents a 60.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Emma Reeve also recently made the following trade(s):

• On Wednesday, November 12th, Emma Reeve sold 7,333 shares of PTC Therapeutics stock. The shares were sold at an average price of $74.50, for a total transaction of $546,308.50.
• On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.50, for a total value of $1,088,787.00.
• On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The stock was sold at an average price of $65.96, for a total value of $1,686,069.52.
• On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The shares were sold at an average price of $59.50, for a total transaction of $934,447.50.

PTC Therapeutics Stock Performance

NASDAQ PTCT traded up $3.10 during trading on Tuesday, reaching $82.93. 4,288,523 shares of the company traded hands, compared to its average volume of 1,139,338. The company has a market cap of $6.66 billion, a price-to-earnings ratio of 11.90 and a beta of 0.60. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $85.62. The stock’s 50 day moving average price is $67.44 and its two-hundred day moving average price is $55.96.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the company posted ($1.39) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Institutional Trading of PTC Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC lifted its position in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares in the last quarter. Optiver Holding B.V. increased its stake in PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 249 shares during the last quarter. Comerica Bank increased its stake in PTC Therapeutics by 868.5% in the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares during the last quarter. Quantbot Technologies LP lifted its position in PTC Therapeutics by 545.5% during the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 551 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of PTC Therapeutics by 84.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 320 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Wells Fargo & Company lifted their price objective on PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Bank of America dropped their price objective on PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, November 5th. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, UBS Group increased their price objective on shares of PTC Therapeutics from $71.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $75.40.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.